Cellarity Appoints Dr. Gregory J. Moore to Board of Directors

Section HeadingSection Content

Somerville, Mass., June 6, 2023 – Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company’s Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem.

“Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation,” said Stephen Berenson, Chairman of Cellarity’s Board of Directors and Managing Partner at Flagship Pioneering. “From his work at Google, Microsoft, and Geisinger, to his clinical experience, Greg has been at the forefront of leveraging data and AI to transform medicine. We welcome Greg’s expertise and guidance as Cellarity advances its platform and uncovers novel biology and treatments across a vast array of disease areas.”

Dr. Moore explained, “Cellarity’s single-cell AI platform is an entirely new approach to drug creation. By embracing the complexity of disease biology and providing novel insights into cellular dysfunction, instead of focusing on a single target, the Cellarity platform can generate novel medicines that otherwise wouldn’t have been discovered. I look forward to helping Cellarity lead a new era of drug discovery.”

“Cellarity has built a unique platform to discover disease modifying treatments at the level of the cell,” said Fabrice Chouraqui, Pharm.D., CEO of Cellarity and a CEO-Partner at Flagship Pioneering. “We look forward to working with Greg and benefitting from his experience at world leading technology companies so that we can continue to unlock the full potential of our platform and uncover new treatments for patients.”

Gregory J. Moore, M.D., Ph.D.

At Microsoft, Dr. Moore was the lead executive responsible for integration of the recent acquisition of Nuance ($19.7 billion) and creation of a new healthcare and life sciences product and engineering division for Microsoft. He is a pioneer in the technology industry, leading the development of cloud-based AI and healthcare data interoperability platforms at two big tech companies to deploy commercial grade enterprise software empowering the healthcare and life sciences industry to provide better care for patients, and to accelerate biomedical research and the development of novel therapeutics. Prior to Microsoft, he served as Vice President at Google and was the founder of Google Cloud Health and Life Sciences. Dr. Moore is board certified in Diagnostic Radiology, Neuroradiology, and Clinical Informatics. Prior to his executive leadership roles at Microsoft and Google, Dr. Moore served as the Chief Emerging Technology and Informatics Officer at Geisinger Health System, where he was also Director of the Institute of Advanced Application, Interim Chair of System Radiology and a practicing neuroradiologist. His prior academic and clinical appointments include Stanford University School of Medicine, Penn State University College of Medicine, and Wayne State University School of Medicine. He currently serves as an independent director on the boards of DaVita (NYSE:DVA) and Olink Holding AB (NASDAQ:OLK).

About Cellarity

Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology.

About Flagship Pioneering

Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $100 billion in aggregate value. To date, Flagship has deployed over $3.1 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 43 transformative companies, including Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Agriculture, Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), and Seres Therapeutics (NASDAQ: MCRB).

CONTACT: Jessica Yingling, Ph.D., press@cellarity.com

Up Next

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases